Cdc25C phosphatase (211-221): inhibits G2 checkpoint [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 16156006 |
| CHEMBL ID | 4297362 |
| SCHEMBL ID | 17101340 |
| MeSH ID | M0507687 |
| Synonym |
|---|
| (2r,5r,8r,11r,14r,17r,20r,23r,26r,29r,32r,35r)-29-((1h-indol-3-yl)methyl)-35-amino-8-(3-amino-3-oxopropyl)-36-(4-benzoylphenyl)-20-(cyclohexylmethyl)-2,5,11,14,17-pentakis(3-guanidinopropyl)-26,32-bis(hydroxymethyl)-4,7,10,13,16,19,22,25,28,31,34-undecaox |
| xh2662798i , |
| d-arginine, 4-benzoyl-d-phenylalanyl-d-seryl-d-tryptophyl-d-seryl-2,3,4,5,6-pentafluoro-d-phenylalanyl-3-cyclohexyl-d-alanyl-d-arginyl-d- arginyl-d-arginyl-d-glutaminyl-d-arginyl- |
| cdc25c phosphatase (211-221) |
| cbp-501 |
| 565434-85-7 |
| cbp501 |
| cbp 501 |
| unii-xh2662798i |
| cbp 501 [who-dd] |
| d-arginine, 4-benzoyl-d-phenylalanyl-d-seryl-d-tryptophyl-d-seryl-2,3,4,5,6-pentafluoro-d-phenylalanyl-3-cyclohexyl-d-alanyl-d-arginyl-d-arginyl-d-arginyl-d-glutaminyl-d-arginyl- |
| SCHEMBL17101340 |
| Q27293833 |
| CHEMBL4297362 |
| DTXSID90205103 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Two phase I dose-escalation studies were conducted to determine the maximum tolerated dose (MTD) and safety profile of the G(2) checkpoint abrogator CBP501, as a single agent and in combination with cisplatin." | ( Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. Bastos, BR; Borad, MJ; Eder, JP; Fernandez, C; Gordon, MS; Kawabe, T; Kufe, DW; Mendelson, DS; Pierceall, WE; Sato, H; Shapiro, GI; Sharma, S; Slough, S; Sutherland, W; Tibes, R; Vogelzang, NJ; Von Hoff, D; Wasserman, E; Weaver, D; Weiss, GJ; Wong, BY, 2011) | 0.37 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.15) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (25.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (62.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||